International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

Congestive Heart Failure: Pathophysiology, Diagnosis and Treatment Strategies: A Review

Shivam Mourya, Dr.Ajeet Pal Singh, Dr. Amar Pal Singh, Hardeep Singh, Deepali Thakur

Department of Pharmacy, St. Soldier Institution of Pharmacy, Lidhran Campus, Behind NIT (R.E.C), Jalandhar -Amritsar ByPass NH-1, Jalandhar 144011, Punjab, India

Date of Submission: 25-03-2025 Date of Acceptance: 05-04-2025

ABSTRACT:
Congestive heart failure (CHF) is defined by the American College of Cardiology (ACC) and the American Heart Association (AHA) as "a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood." Ischemic heart disease is the primary cause of death globally and is also the main contributor to CHF. This condition is prevalent, affecting around 26 million people worldwide, and is associated with high morbidity and mortality rates. CHF leads to increased healthcare costs, decreased functional capacity, and significantly impacts quality of life. Therefore, accurate diagnosis and effective treatment are essential to prevent recurrent hospitalizations, lower morbidity and mortality rates, and improve patientoutcomes.

Congestive heart failure (CHF) is an increasingly common end-stage cardiac condition caused by functional or structural defects that hinder the heart's ability to fill and pump effectively. Patients typically present with cardiopulmonary symptoms, including chest pain, palpitations, and worsening shortness of breath. Notably, many also report abdominal pain, which can be localized or generalized. Right upper quadrant pain may mimic conditions like hepatitis or cholecystitis, often due to hepatic congestion from right heart strain. In cases of new-onset CHF, increased distention of the splanchnic circulation can cause bowel edema, leading to symptoms similar to bowel obstruction, such as abdominal distention and nonfocal pain. It's crucial to evaluate cardiac risk factors and rule out intra-abdominal issues before attributing abdominal pain to CHF. In children and adolescents with new presentations of heart failure, particularly from dilated cardiomyopathies, abdominal complaints like pain, anorexia, nausea, and vomiting are common. Clinicians should maintain a high index of suspicion and include cardiac lab tests, chest radiographs, and bedside echocardiograms in their initial assessment.

Keywords: Congestive Heart Failure (CHF),Systolic Heart Failure, Electrocardiogram(EKG), Echocardiogram, BNP Blood Test

I. INTRODUCTION:

Heart failure occurs when the heart can't pump blood effectively enough to supply the body with the oxygen and nutrients it needs. While the heart doesn't stop working, its efficiency is compromised, causing blood to flow more slowly through the body and raising pressure within the heart.Congestive heart failure (CHF) is a chronic, progressive condition that affects the heart's pumping ability. Although often referred to simply as heart failure, CHF is diagnosed based on symptoms like shortness of breath, leg swelling, difficulty breathing when lying flat (orthopnea), and signs of heart dysfunction observed in an echocardiogram. There are two primary forms of CHF: systolic CHF, where the heart muscle is weak and unable to pump blood effectively, and diastolic CHF, where the heart struggles to fill with blood. In both types, the result is a buildup of fluid in the body.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494



Figure 1. Blood flow Diagram

Table 1 : symptoms showing CHF.

Symptoms : Symptoms you may notice first	**Symptoms that indicate your condition has worsened**	**Symptoms that indicate a severe heart condition**
Fatigue	Irregular heartbeat	Chest pain
Swelling in ankles,feet& legs	Cough from congested lungs	Rapid breathing
Weight gain	Wheezing	Skin appears blue[lack of O2 in lungs]
S]Inc. need to urinate , especially at night	Pulmonary edema causing shortness of breath	fainting



Figure 2, 3. Sign and symptoms.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

II. CAUSES: -

Causes of Congestive Heart Failure include the following:

Coronary artery or heart attack
Cardiomyopathy
Heart issues present at Birth
Diabetes
High Blood pressure (hypertension)
Arrhythmia
A body mass index higher[BMI] than 30
Tobacco and recreational drug use
Alcohol use
Medications such as cancer drugs (Chemotherapy)

III. PATHOPHYSIOLOGY: -

The pathophysiology of congestive heart failure (CHF) involves the heart's inability to pump blood effectively, leading to insufficient oxygen and nutrients being delivered to tissues. This can result from either a reduced pumping ability(systolic dysfunction) or impaired relaxation and filling of the heart (diastolic dysfunction).In CHF, the heart compensates by increasing heart rate, enlarging (dilating), and pumping harder, but over time, these mechanisms become less effective. Fluid buildup occurs due to increased pressure in the heart, which leads to congestion in the lungs (pulmonary edema) and other parts of the body (peripheral edema). Underlying causes of CHF include coronary artery disease, hypertension, valve disorders, and cardiomyopathy, among others. The body's neurohormonal response, involving the activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, exacerbates fluid retention and vasoconstriction, further worsening the heart's workload.

IV. DIFFERENT STAGES OF CHF:

Stage A: - Stage A (pre-heart failure) means you're at increased risk of developing heart failure due to factors such as a family history of congestive heart failure or the presence of one or more related medical conditions:

Hypertension, Diabetes, Metabolic syndrome, History of Rheumatic fever, Family History of Cardiomyopathy.

StageB: - Stage B (pre-heart failure) means your left ventricle is not functioning properly and/or has structural abnormalities, but you have not yet experienced any symptoms of heart failure

StageC:- Individuals with Stage C heart failure have been diagnosed with congestive heart failure and currently experience, or have previously experienced, symptoms of the condition.

StageD:- and reduced EF (Ejection fraction):- People with Stage D HFrEF (heart failure with reduced ejection fraction) have severe symptoms that do not improve with treatment. This is the most advanced stage of heart failure.

Tests to identify CHF , its stage and its cause :-

1. Blood tests
2. Electrocardiogram (EKG or ECG)
3. Chest X-ray
4. Echocardiogram
5. Cardiac catheterization
6. Heart MRI (magnetic resonance imaging)
7. Cardiac computed tomography (CT)
8. Multigated Acquisition Scan (MUGA scan)
9. Stress test
10. Genetic testing

V. ADDITIONAL TESTS:-

1. **Echocardiography**: This test uses sound waves to create an image of the heart, showing how well it's functioning. It helps identify areas of the heart that may be problematic and can detect any damage.
2. **Doppler Imaging**: This technique uses sound waves to assess blood flow speed, direction, and the function of the heart valves.
3. **Holter Monitor**: A Holter monitor is a small device worn in a pouch around your neck or attached to your belt. Electrodes placed on your chest record your heart's rhythm as you go about your daily activities.
4. **Nuclear Heart Scan**: Often part of a stress test, this scan assesses how well blood flows through your heart and how much blood reaches the heart muscle.
5. **Cardiac Catheterization (Angiography)**: In this procedure, a thin, flexible tube (catheter) is inserted into a blood vessel in your arm, thigh, or neck and threaded to your heart. It allows doctors to examine the coronary arteries and measure heart function. A special dye, visible on X-rays, is injected through the catheter to highlight blood flow to the heart muscle.

VI. DIAGNOSIS:-

Medical and family histories play a crucial role in diagnosing congestive heart failure. If you or a family member has a condition that can damage the heart, such as diabetes or coronary artery disease, your risk of developing congestive heart failure is higher. Your doctor will also

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

carefully assess any symptoms you may be experiencing.

A physical exam is typically required. During this exam, your doctor will closely examine your heart and lungs, listening for any unusual sounds and checking for signs of fluid accumulation.

Several specific tests are used together to diagnose congestive heart failure:

VII. EKG (ELECTROCARDIOGRAM):

This test measures your heart rate, checks for irregular rhythms, and can reveal if the heart walls are thicker than usual or if you've had a previous heart attack.

Chest X-ray: This imaging can detect heart enlargement, fluid buildup in the lungs, and lung conditions.

BNP Blood Test: This test measures the level of BNP, a hormone that increases during heart failure.

Cardiac MRI: A cardiac MRI helps identify the underlying causes of heart failure and provides an accurate assessment of the heart's pumping function.

Stress Test: This test helps determine if heart blockages, such as coronary artery disease, are contributing to heart failure, which can inform treatment decisions.

VIII. TREATMENT: -

Ø **Stage A treatment: -**Treatment for people with Stage A heart failure focuses on lifestyle changes and medications to manage underlying risk factors. It includes regular exercise, such as walking every day, and avoiding tobacco products. Managing high blood pressure is crucial, often through a combination of medication, a low-sodium diet, and an active lifestyle. Additionally, controlling high cholesterol is important. Individuals are also advised to avoid alcohol and recreational drugs. If a person has conditions like coronary artery disease, diabetes, high blood pressure, or other vascular or cardiac issues, they may be prescribed angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) to help protect the heart and manage these conditions

Ø. Stage B treatment: - Treatment for people with Stage B heart failure builds on the recommendations for Stage A, with additional medications and possible interventions. In addition to lifestyle modifications, individuals with an ejection fraction (EF) of 40% or lower may be prescribed an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB). If the person has had a heart attack and has an EF of 40% or lower, a beta-blocker may be prescribed, provided they are not already taking one. An aldosterone antagonist is recommended for those who have had a heart attack or have an EF of 35% or lower. In some cases, surgery or other interventions may be necessary to treat underlying issues such as coronary artery blockages, heart attack damage, valve disease (requiring valve repair or replacement), or congenital heart conditions.

Ø Stage C treatment: - Treatment for people with Stage C heart failure with reduced ejection fraction (HFrEF) includes all the measures from Stages A and B, with additional medications and interventions to manage symptoms and slow disease progression. Key treatments include beta-blockers, aldosterone antagonists, and sodium-glucose transport 2 inhibitors (SGLT2i), which help improve heart function. If symptoms persist despite other treatments, a hydralazine/nitrate combination may be used, particularly for African American patients. If the heart rate remains over 70 beats per minute and symptoms continue, medications that slow the heart rate may be prescribed. A diuretic ("water pill") is used to manage fluid retention if symptoms persist. Sodium (salt) restriction is recommended in the diet, and daily weight tracking is crucial, with patients advised to report a weight change of more than 4 pounds to their healthcare provider. In some cases, fluid restriction may also be necessary. Other possible interventions include cardiac resynchronization therapy (biventricular pacemaker) and implantable cardiac defibrillator (ICD) therapy to help manage heart rhythm problems. Even if treatments improve or alleviate symptoms, it is essential to continue therapy to prevent the progression to Stage D heart failure.

Ø **Stage D treatment: -**Treatment for people with Stage D heart failure includes all the treatments for Stages A, B, and C, along with the evaluation for more advanced treatment options. These options may include a heart transplant, ventricular assist devices, or heart surgery to address the underlying heart issues. In some cases, a continuous infusion of inotropic drugs may be used to improve heart function. For patients with severe symptoms and limited treatment options, palliative or hospice care may be considered to focus on comfort and quality of life.

Ø **Stage C & D treatment with preserved EF:-** Treatment for people with Stage C and Stage D heart failure with preserved ejection fraction (HFpEF) includes all the treatments for Stages A

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

and B, along with medications to manage underlying medical conditions that can either cause heart failure or worsen it. These conditions include atrial fibrillation, high blood pressure, diabetes, obesity, coronary artery disease, chronic lung disease, high cholesterol, and kidney disease. A diuretic ("water pill") may be prescribed to reduce or relieve symptoms of fluid retention. It is also essential to carefully manage other health conditions, such as diabetes, kidney disease, anemia, high blood pressure, thyroid disease, asthma, and chronic lung disease. Some of these conditions can have signs and symptoms similar to congestive heart failure. If you experience new or worsening nonurgent symptoms, it is important to inform your healthcareprovider.



IX. VARIOUS DRUGS USED IN THE TREATEMENT OF CHF:-

Treatment for congestive heart failure (CHF) focuses on slowing disease progression, as there is no cure. Cardiologists develop personalized treatment plans, typically involving lifelong medication. If medication is ineffective, surgery to repair heart valves or clear blood vessels may be considered. It's important for patients to report any side effects to their healthcare provider. ACE Inhibitors, Angiotensin-converting enzyme (ACE) inhibitors, such as Lisinopril (Prinivil) and Captopril (Capoten), help lower blood pressure, reduce the heart's workload, and decrease harmful heart-related hormones. Common side effects include dizziness, increased potassium levels, a persistent cough, and changes in kidney function. Patients should have regular blood tests to monitor kidney health.

Angiotensin II Beta Blocker (or Inhibitors):- Angiotensin II receptor blockers (ARBs), such as Valsartan (Diovan) and Losartan (Cozaar), work similarly to ACE inhibitors but generally cause fewer issues with dry cough. Like ACE inhibitors, ARBs can affect kidney function, so kidney function tests are recommended. Common side effects include dizziness, changes in kidney function, and elevated potassium levels.

Beta Blockers:-Beta blockers, such as Metoprolol (Toprol) and Carvedilol (Coreg), slow the heart rate and reduce the force of heartbeats, helping to lower blood pressure. Common side effects include fatigue, dizziness, drowsiness, headache, and upset stomach. It's important not to stop taking a beta blocker without consulting a healthcare provider.

Diuretics:-Diuretics, often called "water pills," remove excess fluid from the body but can also cause potassium loss, sometimes requiring potassium supplements. Drugs in this class include Furosemide (Lasix), Bumetanide (Bumex), and Metolazone (Zaroxolyn). Common side effects

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

include dizziness, frequent urination, skin rash, changes in kidney function, increased blood sugar, gout, and dehydration.

Aldosterone Antagonists:-Aldosterone antagonists, such as Eplerenone (Inspra) and Spironolactone (Aldactone), help prevent the body from producing excess aldosterone, a hormone that can harm the heart. Common side effects include breast swelling or tenderness in both men and women, increased potassium levels, and changes in kidney function. Patients should have regular kidney and potassium tests.

Digoxin:-Digoxinis a medication that slows the heart rate and can help improve the heart's pumping ability. Blood tests are necessary to determine the correct dosage. Common side effects include digestive issues, poor appetite, and nausea.

IsosorbideDinitrate:-This medication helps relax blood vessels and reduce strain on the heart. It is particularly beneficial for treating heart failure in African Americans and has been shown to lower the risk of death, according to the National Heart, Lung, and Blood Institute.Certain medications can worsen the health of a patient with congestive heart failure (CHF) by increasing fluid buildup, raising blood pressure, or putting additional strain on the heart. It's important for patients with CHF to avoid these medications unless directed otherwise by their healthcare provider.



Figure 5. Ways To Reduce Riske Of Developing Heart Failure.

1. **Painkillers**: NSAIDs (e.g., ibuprofen) and COX-2 inhibitors
2. **Anesthesia agents**: Desflurane, enflurane, halothane, and others
3. **Diabetes medications**: Metformin, Onglyza (saxagliptin), Januvia (sitagliptin), Actos (pioglitazone), Avandia (rosiglitazone)
4. **Alpha-blocker**: Doxazosin
5. **Calcium channel blocker**: Verapamil
6. **Hair growth treatments**: Minoxidil
7. **Antifungal medications**: Itraconazole
8. **Chemotherapy drugs**: Including Taxotere (docetaxel)
9. **Antidepressants**: Such as Celexa (citalopram)

Note:-Patients with CHF should consult their healthcare provider before starting or stopping any of these medications**.**

X. LIFESTYLE CHANGES:-

1. Diet and Exercise

Diet: Reducing sodium intake is crucial to prevent fluid retention, which worsens CHF symptoms. Avoid processed foods, canned soups, and fast food. Limiting alcohol and fluid intake can also help reduce heart strain. Doctors provide specific fluid guidelines based on individual needs.

Exercise: Regular aerobic exercise (e.g., walking, cycling) strengthens the heart, improves stamina, and lowers blood pressure. Patients should work with their healthcare provider to create a tailored exercise plan, as some may need to start with low-

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

impact activities. Cardiac rehabilitation may be beneficial for some

2. **Fluid Restriction:** Excess fluid retention is common in CHF. Fluid intake may need to be limited to avoid exacerbating symptoms and reduce the workload on the heart. Patients should follow their doctor's recommendations for safe fluid intake and stay hydrated within those limits.
3. **Weight Management:**Maintaining a healthy weight is key, as obesity increases the strain on the heart. However, weight loss should be gradual, as rapid weight loss may signal fluid loss or other complications. Daily weight monitoring helps track fluid retention, which can guide medication adjustments.
4. **Other Lifestyle Considerations** .

Smoking cessation: Quitting smoking improves heart health and reduces CHF risks.
Stress management: Practices like meditation and deep breathing can help manage stress, which affects heart function.
Adequate sleep: Proper rest is vital to managing fatigue and improving heart health.

REFERENCES:-

[1]. Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed]

[2]. Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med SciMonit. 2023 Mar 06;29:e939020. [PMC free article] [PubMed]

[3]. Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article] [PubMed]

[4]. Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article] [PubMed]

[5]. DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article] [PubMed]

[6]. Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am CollCardiol. 2013 Nov 12;62(20):1845-54. [PubMed]

[7]. Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J PrevCardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article] [PubMed]

[8]. Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article] [PubMed]

[9]. Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article] [PubMed]

[10]. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed]

[11]. Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed]

[12]. Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article] [PubMed]

[13]. Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article] [PubMed]

[14]. Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed]

[15]. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed]

[16]. DiNicolantonio JJ, Liu J, O'Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. ProgCardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed]

[17]. Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am CollCardiol. 2016 Aug 02;68(5):473-482. [PubMed]

[18]. Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article] [PubMed]

[19]. Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed]

[20]. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed]

[21]. Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed]

[22]. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am CollCardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed]

[23]. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, 41.Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article] [PubMed]

[24]. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O'Donnell M, McKee M, Dagenais G. Modifiable risk

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1032-1040 www.ijprajournal.com ISSN: 2456-4494

factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article] [PubMed]

[25]. AitMou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob CardiolSciPract. 2015;2015:10. [PMC free article] [PubMed]

[26]. Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article] [PubMed]

[27]. Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association WithNeurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article] [PubMed]

[28]. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article] [PubMed]

[29]. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article] [PubMed]

[30]. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article] [PubMed]

[31]. King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed]

[32]. Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed]

[33]. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed]

[34]. Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed

[35]. Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed